TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06991257: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)

Sponsor: Pfizer · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 620 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$4,847,200

Rescue Site Savings

+$3,187,200

Unlock Full NCT06991257 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06991257 Rescue Dossier →